Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2010 Oct 1;116(19):4487-94. doi: 10.1002/cncr.25431.
The prognosis of patients with localized gastroesophageal carcinoma (LGC) can be defined after chemoradiation by the standardized uptake value (SUV) of positron emission tomography (PET). High SUV (HSUV) after chemoradiation portends a poor prognosis. The authors retrospectively examined the role of surgery in patients with HSUV after chemoradiation.
The authors analyzed the postchemoradiation PET scans of 204 LGC patients. One hundred twenty-nine patients had HSUV. Two postchemoradiation variables were evaluated: SUV and surgery and their association with overall survival (OS) and event-free survival (EFS). The log-rank test, multivariate Cox proportional hazards model, and Kaplan-Meier survival plots were used to assess the association between OS or EFS and the dichotomized SUV (using the median SUV as the cutoff) and surgery.
The median SUV was 4.6. The OS of the 52 patients who had an SUV above the median and did not undergo surgery (HSUV-NS) (median OS, 1.22 years; 95% confidence interval [95% CI], 1.02-2.16 years) was much shorter than that of the 77 patients with an SUV above the median who underwent surgery (HSUV-S) (median OS, 2.7 years; 95% CI, 2.43 years to not reached [P<.0001]). Similarly, the EFS for patients with HSUV-NS was significantly shorter than that for patients with HSUV-S (P=.001). In the multivariate analyses, patients who underwent surgery (irrespective of SUV) had a lower risk of death (P=.0001) and disease progression (P=.002).
The data from the current study suggest that surgery may prolong OS and EFS in patients with a poor prognosis after chemoradiation as defined by PET. However, these data need confirmation.
通过正电子发射断层扫描(PET)的标准化摄取值(SUV)可以对局限性胃食管癌(LGC)患者的预后进行定义。放化疗后 SUV 高(HSUV)预示预后不良。作者回顾性研究了放化疗后 HSUV 患者手术的作用。
作者分析了 204 例 LGC 患者放化疗后的 PET 扫描。129 例患者 HSUV。评估了放化疗后两个变量:SUV 和手术及其与总生存期(OS)和无事件生存期(EFS)的关系。采用对数秩检验、多因素 Cox 比例风险模型和 Kaplan-Meier 生存曲线评估 OS 或 EFS 与 SUV 二分(以 SUV 中位数为界)和手术的关系。
SUV 中位数为 4.6。SUV 高于中位数且未行手术(HSUV-NS)的 52 例患者的 OS(中位 OS,1.22 年;95%置信区间[95%CI],1.02-2.16 年)明显短于 SUV 高于中位数且行手术的 77 例患者(HSUV-S)(中位 OS,2.7 年;95%CI,2.43 年至未达到[P<.0001])。同样,HSUV-NS 患者的 EFS 明显短于 HSUV-S 患者(P=.001)。多因素分析中,手术患者(无论 SUV 如何)死亡风险(P=.0001)和疾病进展风险(P=.002)均较低。
本研究数据表明,对于 PET 定义的放化疗后预后不良的患者,手术可能延长 OS 和 EFS。但是,这些数据需要确认。